Sustained #vaccine #exposure elicits more rapid, consistent, and broad #humoral immune responses to multivalent #influenza #vaccines
Source: BioRxIV, AbstractWith the ever-present threat of pandemics, it is imperative we develop vaccine technologies eliciting broad and durable immunity to high-risk pathogens. Yet, current annual influenza vaccines, for example, fail to provide robust immunity against the 3-4 homologous strains they contain, let alone heterologous…
Source: BioRxIV, AbstractWith the ever-present threat of pandemics, it is imperative we develop vaccine technologies eliciting broad and durable immunity to high-risk pathogens. Yet, current annual…
A synthetic #TLR4 agonist significantly increases #humoral immune #responses and the protective ability of an #MDCK-cell-derived inactivated #H7N9 #vaccine in #mice, Arch Virol.: https://link.springer.com/article/10.1007/s00705-024-06082-8
Antigenically divergent H7N9 viruses pose a potential threat to public #health, with the poor #immunogenicity of candidate H7N9 vaccines demonstrated in clinical trials underscoring the urgent need for more-effective H7N9 vaccines.
Antigenically divergent H7N9 viruses pose a potential threat to public health, with the poor immunogenicity of candidate H7N9 vaccines demonstrated in clinical trials underscoring the urgent need for more-effective H7N9 vaccines. In the present study, mice were immunized with various doses of a suspended-MDCK-cell-derived inactivated H7N9 vaccine, which was based on a low-pathogenic H7N9 virus, to assess cross-reactive immunity and cross-protection against antigenically divergent H7N9 viruses. We found that the CRX-527 adjuvant, a synthetic TLR4 agonist, significantly enhanced the humoral immune responses of the suspended-MDCK-cell-derived H7N9 vaccine, with significant antigen-sparing and immune-enhancing effects, including robust virus-specific IgG, hemagglutination-inhibiting (HI), neuraminidase-inhibiting (NI), and virus-neutralizing (VN) antibody responses, which are crucial for protection against influenza virus infection. Moreover, the CRX-527-adjuvanted H7N9 vaccine also elicited cross-protective immunity and cross-protection against a highly pathogenic H7N9 virus with a single vaccination. Notably, NI and VN antibodies might play an important role in cross-protection against lethal influenza virus infections. This study showed that a synthetic TLR4 agonist adjuvant has a potent immunopotentiating effect, which might be considered worth further development as a means of increasing vaccine effectiveness.
Evaluating #Humoral #Immunity Elicited by #XBB15 Monovalent #COVID19 #Vaccine, Emerg Infect Dis.: https://wwwnc.cdc.gov/eid/article/30/6/24-0051_article
We report boosting of #IgG (2.1×), #IgA (1.5×), and total IgG/A/M (1.7×) targeting the #spike receptor-binding domain and neutralizing titers against WA1 (2.2×), XBB.1.5 (7.4×), #EG51 (10.5×), and #JN1 (4.7×) variants.
[Correspondence] #Humoral immune #responses to the monovalent #XBB15-adapted BNT162b2 #mRNA #booster in #Sweden https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00779-X/fulltext?rss=yes
-- In summary, monovalent XBB.1.5-adapted booster vaccination substantially enhanced both binding and neutralising antibody responses against a spectrum of variants in an older population with four or more previous vaccine doses.
Despite the success of existing COVID-19 vaccine platforms, the persistent limitations in global deployment of vaccines and waning immunity exhibited by many of the currently deployed vaccine platforms have led to perpetual outbreaks of SARS-CoV-2 variants of concern. Thus, there is an urgent need to develop new durable vaccine candidates, to expand the global vaccine pipeline, and provide safe and effective solutions for every country worldwide. Here we deeply profiled the functional humoral response induced by two doses of AS03-adjuvanted and non-adjuvanted plant-derived Coronavirus-like particle (CoVLP) vaccine candidate from the phase 1 clinical trial, at peak immunogenicity and six months post-vaccination. AS03-adjuvanted CoVLP induced robust and durable SARS-CoV-2 specific humoral immunity, marked by strong IgG1antibody responses, potent FcγR binding, and antibody effector function. Contrary to a decline in neutralizing antibody titers, the FcγR2A-receptor binding capacity and antibody-mediated effector functions, such as opsonophagocytosis, remained readily detectable for at least six months.
Angstrom Minerals
Giuseppe Michieli